The Src family kinase inhibitor dasatinib delays pain-related behaviour and conserves bone in a rat model of cancer-induced bone pain
Abstract Pain is a severe and debilitating complication of metastatic bone cancer. Current analgesics do not provide sufficient pain relief for all patients, creating a great need for new treatment options. The Src kinase, a non-receptor protein tyrosine kinase, is implicated in processes involved i...
Guardado en:
Autores principales: | Camilla Kristine Appel, Simone Gallego-Pedersen, Line Andersen, Sophie Blancheflor Kristensen, Ming Ding, Sarah Falk, Manasi Sayilekshmy, Charlotte Gabel-Jensen, Anne-Marie Heegaard |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8a2be61aace84981bb8033b783094820 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects.
por: Antonio Garcia-Gomez, et al.
Publicado: (2012) -
Effect of glutaminase inhibition on cancer-induced bone pain
por: Fazzari J, et al.
Publicado: (2019) -
Transcriptome Sequencing Explores the Mechanism of Baicalin on Bone Cancer Pain
por: Wang A, et al.
Publicado: (2021) -
BONE MINERAL DENSITY IN PATIENTS WITH CHRONIC LOW BACK PAIN
por: Tariq Aziz, et al.
Publicado: (2018) -
STING suppresses bone cancer pain via immune and neuronal modulation
por: Kaiyuan Wang, et al.
Publicado: (2021)